Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric pulses vs. pelvic tumors: a new hope when surgery fails?

NCT ID NCT07782164

Disease control Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study looks at whether irreversible electroporation (IRE) can safely and effectively treat recurrent pelvic tumors in people who cannot have surgery, radiation, or other local treatments. IRE uses electrical pulses to destroy cancer cells without cutting or heating tissue. Researchers will track side effects, nerve damage, and how long patients live without the tumor growing back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Irreversible electroporation (IRE), a procedure using electrical pulses to destroy tumor cells
What this could lead to
If IRE proves safe and effective, it could offer a new treatment option for people with recurrent pelvic tumors who have run out of standard choices like surgery or radiation.
What could go wrong
This is a small observational study, so results may not apply broadly. IRE carries risks like nerve injury, and its long-term effectiveness is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive patients treated with irreversible electroporation (IRE) for recurrent pelvic tumors at Amsterdam UMC starting from December 2012, identified from a dedicated institutional registry. Patients had recurrent pelvic disease not amenable to other local treatment options (surgery, stereotactic body radiotherapy, or thermal ablation), as determined by a multidisciplinary tumor board including medical oncology, radiation oncology, surgical oncology, diagnostic and interventional radiology, and pathology.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Measurable disease described on pre-treatment imaging (CT/MRI/PET-CT) (max 6 weeks prior); * IRE of a recurrent pelvic tumor; * Unsuitable for other local therapies (surgery/stereotactic body radiation therapy) as described during the multidisciplinary tumor board; Exclusion Criteria: * If the treated tumor was biopsied directly prior to MWA and pathology proves the lesion to represent a benign entity; * Inadequate or insufficient data registered; * Inadequate or insufficient follow-up;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma anus neoplasm cervical cancer colorectal carcinoma colorectal neoplasm kidney cancer lung cancer lung neoplasm Neoplasm Recurrence, Local ovarian cancer prostate cancer Recurrence renal carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anal cancer Bladder cancer Cervical cancer Colorectal carcinoma Lung cancer (including metastatic cancer) Neoplasm recurrence, local Ovarian cancer Pelvic cancer Pelvic tumor recurrence Prostate cancer Renal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, North Holland, 1118 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.